Crohn's Disease News and Research

Latest Crohn's Disease News and Research

Celgene reports total revenue of $758M for fourth-quarter of 2009

Celgene Corporation announced non-GAAP (Generally Accepted Accounting Principles) net income of $290.3 million, or non-GAAP diluted earnings per share of $0.62 for the quarter ended December 31, 2009. Non-GAAP net income for the fourth quarter of 2008 was $200.9 million or non-GAAP diluted earnings per share of $0.43. Based on U.S. GAAP, Celgene reported net income of $254.2 million, or diluted earnings per share of $0.54 for the quarter ended December 31, 2009. GAAP net loss for the fourth quarter of 2008 was $149.3 million, or diluted loss per share of $0.33.

28 Jan 2010

DNA variations in genes increase risk of developing PI-IBS

Studies of the victims of the Walkerton, Ont. tainted drinking water tragedy have led researchers to discover DNA variations in genes that increase the risk of developing post-infectious irritable bowel syndrome (PI-IBS). The sheer scale of infection and the recording of the health of Walkerton's citizens gave a team of researchers a unique opportunity to study the origin of this disorder.

28 Jan 2010

Vitamin D supplements can counter the effects of Crohn's disease

A new study has found that Vitamin D, readily available in supplements or cod liver oil, can counter the effects of Crohn's disease. John White, an endocrinologist at the Research Institute of the McGill University Health Centre, led a team of scientists from McGill University and the Universit- de Montr-al who present their findings about the inflammatory bowel disease in the latest Journal of Biological Chemistry.

27 Jan 2010

Abbott declares quarterly dividend of 40 cents per share

Abbott today announced financial results for the fourth quarter ended Dec. 31, 2009.

27 Jan 2010

Mice study shows obesity can increase risk of developing liver cancer

Obesity comes with plenty of health risks, but there's one that's perhaps not so well known: an increased risk of developing cancer, and especially certain types of cancer like liver cancer. Now, a group of researchers reporting in the January 22nd issue of the journal Cell, a Cell Press publication, have confirmed in mice that obesity does indeed act as a "bona fide tumor promoter." They also have good evidence to explain how that happens.

22 Jan 2010

Research article addressing incidental findings in MRI-enterography in patients with CD to be published

MRI is increasingly used in the assessment of small bowel CD. Unlike conventional radiology, MRI enables visualization of disease extension beyond the intestinal wall, i.e., abscesses and fistulas. However, some extra-intestinal findings are unexpected and without relation to CD.

18 Jan 2010

Medical Marijuana praises New Jersey State Assembly for removing state-wide penalties on marijuana use

Medical Marijuana Inc applauds the New Jersey State Assembly and Senate for having approved "The New Jersey Compassionate Use Medical Marijuana Act" on Monday, January 11, 2010. A804/S119 removes state-wide penalties for possession of up to two ounces of marijuana when a New Jersey licensed Physician recommends it for one of the qualified medical conditions including Aids, Cancer, Multiple Sclerosis and Crohn's disease among others.

13 Jan 2010

Preliminary results from Nektar Therapeutics' NKTR-102 Phase 2 study in platinum-resistant ovarian cancer

Nektar Therapeutics today announced preliminary results from the first stage of a two-stage Phase 2 clinical study evaluating NKTR-102 in women with platinum-resistant ovarian cancer. In the first stage of the study, 39 patients enrolled with platinum-resistant disease were evaluable for the primary endpoint of overall response rate using Gynecologic Cancer InterGroup (GCIG) criteria, i.e., a combination of response by tumor imaging

12 Jan 2010

GSK exercises option to obtain exclusive license to develop and commercialize Traficet-EN

GlaxoSmithKline (GSK) and ChemoCentryx, Inc. today announced that GSK has exercised its option to obtain an exclusive license for further development and worldwide commercialization of Traficet-EN(TM) (CCX282-B), a specific CCR9 antagonist with the potential to offer a new approach for the treatment of inflammatory bowel diseases, including Crohn's disease.

12 Jan 2010

University of Western Ontario receives grant to conduct randomized trial for Crohn's disease

Robarts Clinical Trials at The University of Western Ontario in London, Canada, has been awarded a 4.7 million dollar grant to conduct a randomized controlled trial evaluating treatment options for Crohn's disease.

5 Jan 2010

La Jolla Institute for Allergy & Immunology awarded $18.8M NIH grant for infectious diseases study

Researchers from the La Jolla Institute for Allergy & Immunology will take aim at several of the world's most dangerous infectious diseases - tuberculosis, malaria and dengue virus -- in a five-year, $18.8 million federally-funded set of projects seeking to make new inroads toward vaccines against the disorders.

17 Dec 2009

Cannabis for Ulcerative Colitis and Crohn's Disease treatment

Chemicals found in cannabis could prove an effective treatment for the inflammatory bowel diseases Ulcerative Colitis and Crohn's Disease, say scientists.

17 Dec 2009

People are more prone to Crohn's disease and ulcerative colitis, explains new research

New research by the University of Adelaide could help explain why some people are more prone to Crohn's disease, ulcerative colitis and other autoimmune diseases.

17 Dec 2009

ChemoCentryx commences enrollment in CCX354 Phase 2 clinical trial for RA

ChemoCentryx, Inc. today announced that it has begun enrolling patients in a Phase 2 clinical trial of CCX354, an orally-bioavailable, novel, small molecule drug designed to specifically target the CCR1 chemokine receptor for the treatment of rheumatoid arthritis (RA).

16 Dec 2009

Proposed guidelines for regulating medical marijuana dispensary businesses released

Coloradans for Medical Marijuana Regulation, a coalition of medical marijuana patients, providers and growers supporting responsible regulation of medical marijuana, today released proposed guidelines for regulating medical marijuana dispensary businesses that would protect the commercial enterprises and their patients, and promote public safety.

16 Dec 2009

Eggs of marine animals is the best dietary source of Omega 3 fatty acids

The roe of hake, lumpsucker and salmon is the best dietary source of Omega 3, according to a study carried out by researchers at the University of Almer-a (UAL). The scientists analysed the eggs, or roe, of 15 marine animals, and found all of these contained high levels of these fatty acids, which are essential to the human body.

14 Dec 2009

Decision Resources reports increased uptake of TNF-alpha inhibitors for Crohn's disease

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that compared to last year's analysis of U.S. patient-level claims data, TNF-alpha inhibitors are being used more often to treat newly diagnosed patients suffering from Crohn's disease.

9 Dec 2009

Additional data from ChemoCentryx' study of Traficet-EN in Crohn's disease patients

In addition to data released in late November, ChemoCentryx, Inc., announced today more data from the Company's PROTECT-1 (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial) of Traficet-EN(TM) (CCX282-B) in patients with moderate-to-severe Crohn's disease.

8 Dec 2009

HESG to acquire stake in two Montana-based marijuana companies

Health Sciences Group, Inc. would like to announce that it is in strong negotiations to acquire a minority stake in two separate Montana-based marijuana growing, distribution and care giving operations.

5 Dec 2009

Amber Pharmacy receives ACHC accreditation

Amber Pharmacy announced today that it received accreditation by the Accreditation Commission for Health Care, Inc. (ACHC) for specialized pharmacy services.

4 Dec 2009

Crohn's Disease News and Research

Latest Crohn's Disease News and Research

Celgene reports total revenue of $758M for fourth-quarter of 2009

DNA variations in genes increase risk of developing PI-IBS

Vitamin D supplements can counter the effects of Crohn's disease

Abbott declares quarterly dividend of 40 cents per share

Mice study shows obesity can increase risk of developing liver cancer

Research article addressing incidental findings in MRI-enterography in patients with CD to be published

Medical Marijuana praises New Jersey State Assembly for removing state-wide penalties on marijuana use

Preliminary results from Nektar Therapeutics' NKTR-102 Phase 2 study in platinum-resistant ovarian cancer

GSK exercises option to obtain exclusive license to develop and commercialize Traficet-EN

University of Western Ontario receives grant to conduct randomized trial for Crohn's disease

La Jolla Institute for Allergy & Immunology awarded $18.8M NIH grant for infectious diseases study

Cannabis for Ulcerative Colitis and Crohn's Disease treatment

People are more prone to Crohn's disease and ulcerative colitis, explains new research

ChemoCentryx commences enrollment in CCX354 Phase 2 clinical trial for RA

Proposed guidelines for regulating medical marijuana dispensary businesses released

Eggs of marine animals is the best dietary source of Omega 3 fatty acids

Decision Resources reports increased uptake of TNF-alpha inhibitors for Crohn's disease

Additional data from ChemoCentryx' study of Traficet-EN in Crohn's disease patients

HESG to acquire stake in two Montana-based marijuana companies

Amber Pharmacy receives ACHC accreditation

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Crohn's Disease News and Research

Latest Crohn's Disease News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in